CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Bristol Myers Squibb CO (BMY) / repotrectinib
Forward catalyst · BMY

repotrectinib

Sponsor Bristol Myers Squibb CO · listed as BMY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

repotrectinib is a drug asset sponsored by Bristol Myers Squibb CO, listed as BMY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Feb 16, 2027 (day precision, medium confidence), tied to trial NCT06140836. That trial is in Phase 3 and currently active not recruiting, studying Carcinoma, Non-Small-Cell Lung.

Next catalyst

Event typeREADOUT
Expected date2027-02-16
As disclosedFeb 16, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06140836
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorBristol-Myers Squibb
Listed asBMY
Condition(s)Carcinoma, Non-Small-Cell Lung
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More BMY catalysts

Related catalysts and sponsor